Autotransfusion Devices Market Size, Share & Industry Analysis, By Product Type (Autotransfusion Systems and Consumables & Accessories) By Application (Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, Obstetrics & Gynecological Surgeries, and Others) By End User (Hospitals and Specialty Clinics & Others) and Regional Forecast, 2019-2026

The global autotransfusion devices market size stood at USD 249.2 million in 2018 and is projected to reach USD 320.5 million by 2026, exhibiting a CAGR of 3.2% during the forecast period.

We are in process of revamping Autotransfusion Devices Market with respect to COVID-19 Impact.

Request Sample

Autotransfusion devices are widely used for collection and reinfusion of patient’s own blood. These systems play a major role in cell salvage techniques, enabling autologous blood transfusion with an aim to reduce the risk of infections associated with allogeneic blood transfusions. These devices are widely used in cardiovascular, orthopedic, neurological, obstetrics & gynecological, and other invasive surgeries. As per the usability of systems, autotransfusion systems can be categorized into intraoperative systems, postoperative systems, and dual-mode systems.

Request a Free sample to learn more about this report.

An extensively increasing number of surgical procedures across the globe is anticipated to boost the growth of the market during the forecast period. Moreover, the ageing population, increasing prevalence of chronic conditions, and need for advanced blood management systems are likely to boost the autotransfusion devices market growth during the forecast period.

The market is witnessing several technological advancements and trends. The adoption of autotransfusion devices is expected to witness growth in developed and developing countries owing the exponentially increasing number of surgical procedures.

MARKET DRIVERS

“Scarcity of Donated Blood to Drive the Growth of Autotransfusion Devices”

Major invasive surgeries are generating huge demand for allogeneic blood in developed as well as developing countries. This, combined with factors such as the geriatric population, an increasing number of surgical procedures, and increasing incidence of critical injuries, are likely to increase the burden on blood supply. Moreover, fewer blood donations in contrast with increasing number of surgical procedures, are projected to boost the adoption of market during the forecast period. For instance, according to a study conducted by World Health Organization (WHO) in 2016, the patient group over 60 years had the highest consumption of allogeneic blood, accounting for an estimated 79.0% of the total blood transfusion that took place in the developed regions. This, combined with other applications of blood such as plasma fractionation, contingency requirement, and others are expected to generate scarcity of blood, representing a potential opportunity for the growth of the autotransfusion devices market during the forecast period.

Furthermore, the requirement of blood transfusion is directly co-related with national health policy, level of healthcare infrastructure, and distribution of health services in that particular region. Poor management of these factors is highly probable to impact on blood transfusion practices, which will subsequently boost the growth of the market during 2019-2026.

“Increasing Number of Surgical Procedures to Boost the Adoption of Autotransfusion Devices”

Increasing use of intraoperative & postoperative cell salvage in exponentially increasing number of surgical procedures are likely to drive the autoatransfuion devices market growth. Additionally, the rising awareness regarding the complications associated with the allogeneic transfusions and an increasing number of high-bleeding surgeries are factors projected to accelerate the autotransfusion devices market revenue during the forecast period. For instance, according to study conducted by Department of Surgery, University of Pennsylvania, Philadelphia, US, the number of open hernia procedures represented growth of an estimated 12.0% during 2009-2013 in the U.S. Moreover, according to study conducted by OECD, the number of cesarean section procedures in the UK grew from 204,057 in 2016 to 206,620 in 2017.

SEGMENTATION

By Product Type Analysis

“Autotransfusion Systems Segment to Dominate the Market”

In terms of product type, the market is categorized into autotransfusion systems and consumables & accessories. Autotransfusion systems are further classified as intraoperative autotransfusion systems, postoperative autotransfusion systems, and dual-mode autotransfusion systems. Increasing adoption of autotransfusion systems in developed, as well as developing countries, are likely to boost the growth of the autotransfusion systems segment in the market during the forecast period. Additionally, improved flexibility, transfusion report generations, and connectivity are projected to drive the growth of the dual-mode market by 2026.

To know how our report can help streamline your business, Speak to Analyst

Furthermore, higher adoption and utilization of autotransfusion systems are anticipated to offer substantial opportunities for the growth of the consumables & accessories segment in the market. This, combined with growing emphasis on intraoperative cell salvage during major invasive surgeries, is likely to boost the growth of the consumables & accessories segment in the market during the forecast period. 

 By Application Analysis

“Cardiovascular Surgeries is Anticipated to Dominate the Segment”

On the basis of application, the market can be segmented into cardiovascular surgeries, orthopedic surgeries, neurological surgeries, obstetrics & gynecological surgeries, and others. In terms of revenue, the cardiovascular surgeries segment is estimated to dominate the autotransfusion devices market owing to the higher utilization of autotransfusion devices during cardiovascular surgical procedures. Moreover, increasing number of cardiovascular procedures such as CABG, ICD & pacemaker implantations, heart transplantations, valve replacement surgeries, and others are anticipated to register significant CAGR during the forecast period. Adoption of postoperative cell salvage in orthopedic surgeries is expected to drive the growth of the orthopedic surgeries in the application segment. Additionally, invasive surgeries such as caesarian section, and others are anticipated to drive the obstetrics & gynecological surgeries application segment in the global market. The increasing number of spinal procedures are offering significant opportunity for the growth of the neurological application segment.  

By End User Analysis

“Increasing number of Surgical Procedures in Hospitals to Lead Hospitals Segment”

On the basis of the end user, the market is segmented into hospitals, and specialty clinics & others. The hospitals segment is estimated to dominate the market throughout the forecast period. Increasing number of cardiovascular and obstetrics & gynecological surgeries in hospitals are projected to drive the hospitals segment during the forecast period. Certain factors such as evolving healthcare infrastructure in developing countries and increasing number of advanced healthcare facilities are likely to boost the adoption of autotransfusion devices in hospitals, which will eventfully accelerate the growth of the hospital segment in the autotransfusion devices market.

Combined with this, increasing number of advanced trauma centers, cardiovascular centers, emergency centers, etc. are likely to boost the adoption of autotransfusion devices in specialty clinics. Moreover, increasing adoption of intraoperative and postoperative cell salvage in specialty clinics, especially in developed regions is anticipated to offer significant growth for the specialty clinics & others segment by 2026.

REGIONAL ANALYSIS

North America generated a revenue of USD 125.8 million in 2018 and is projected to dominate the market throughout the forecast period. Increasing focus on autologous blood transfusion in major cardiovascular & orthopedic surgeries coupled with developed infrastructure is anticipated to drive the region during the forecast period.

To get more information on the regional analysis of this market, Request a Free sample

In Europe, the rapidly increasing number of surgeries coupled with strong emphasis on the adoption of intraoperative and postoperative cell salvage techniques are likely to offer substantial opportunity for the growth of the market in the region. Moreover, massive burden of allogeneic blood transfusion and increased efficiency in blood transfusion in countries such as the UK, France, Germany, and others are anticipated to drive the market in the region. For instance, according to a study conducted by Cochrane in 2010, the use of autotransfusion systems in orthopedic and cardiovascular surgical procedures showed an average saving of 0.7 units of blood per patient.

In Asia Pacific, entrance of new market players and growing awareness on cell salvage technologies are projected to drive the growth of the region by 2026. Moreover, rapidly increasing number of surgical procedures and developing healthcare infrastructure in countries such as China & India is anticipated to offer significant growth opportunities in the region. In rest of the world, increasing number of healthcare facilities are anticipated to boost the growth of the autologous blood transfusion devices market in the region.  

INDUSTRY KEY PLAYERS

“LivaNova Plc and Haemonetics Corporation to Dominate the Market.”

The autotransfusion devices market is a highly consolidated market as a limited number of players hold majority of the market share. In 2018, LivaNova Plc., Haemonetics Corporation, and Fresenius SE & Co. KGaA held majority of the market share. In terms of revenues, LivaNova Plc accounted for the major share, which is mainly due to strong brand presence, robust distribution channels, and strong network of hospitals in majority part of the world. The market share of Haemonetics Corporation and Fresenius SE & Co. KGaA is anticipated to increase over the forecast period due to continuous product introductions, strategic distribution partnerships, and focus on market penetration in developing regions.  

LIST OF KEY COMPANIES PROFILED:

• Haemonetics Corporation


• LivaNova PLC


• Medtronic


• Fresenius SE & Co. KGaA


• BD (Becton, Dickinson and Company)


• Beijing Jingjing Medical Equipment Co., Ltd.


• Other Prominent Players

REPORT COVERAGE

The report presents a comprehensive assessment of the global market by offering valuable insights, facts, industry-related information, and historical data. Several methodologies and approaches are adopted to make meaningful assumptions and views. Furthermore, the report offers a detailed analysis and information as per the market segments, helping our readers to get a comprehensive overview of the market.

An Infographic Representation of Autotransfusion Devices Market

View Full Infographic

To get information on various segments, share your queries with us

Along with this, the report provides an elaborative analysis of the global autologous blood transfusion devices market dynamics and competitive landscape. Various key insights presented in the report are the key industry developments: mergers, acquisitions & partnerships, new product launches by key players, number of major cardiovascular procedures in key countries 2018, number of major orthopedic procedures in key countries 2018, and number of major obstetrics & gynecological procedures in key countries 2018.

To gain extensive insights into the market, Request for Customization

REPORT SCOPE & SEGMENTATION

INDUSTRY DEVELOPMENTS:

• In December 2019, Haemonetics Corporation launched Next Generation SafeTrace Tx Transfusion Management Software in North America. The newly released software is equipped with enhanced user experience and superior operational workflow enabling extended quality of care.


• In July 2018, Medtronic got FDA approval for its advanced autoLog IQ Autotransfusion System. The newly approved system offers postoperative autotransfusion mechanisms in cardiovascular, orthopedics, neurology, and other types of surgeries.


• In December 2017, BD announced the acquisition of Bard (C. R. Bard, Inc.), leading to the creation of a new global healthcare leader and enhanced growth opportunities for the company. Also, by acquiring Bard, the company entered into manufacturing and distribution of market.